C-CAR011

CBM.CD19嵌合抗原受体T细胞

Report date: 2023/05/05 17:41:41

Base Information

Drug NameC-CAR011
Drug Alias NameCBM.CD19嵌合抗原受体T细胞注射液CD19 specific CART cellsAnti-CD19 CART cell therapy - Cellular Biomedicine GroupAnti-CD19 CART cells
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGene transferenceCytotoxic T lymphocytes stimulantsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPla General Hospital
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesCellular Biomedicine Group LtdShanghai Cellular Biopharmaceutical Group LtdCellular Biomedicine (Shanghai) Co Ltd
Active IndicationsLymphoma, B-Cell
Inactive IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[6] 

Other Information

ATC CodeN/A
Related LinksN/A